NCT07144631 Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome
| NCT ID | NCT07144631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rhode Island Hospital |
| Condition | Restless Leg Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2025-10-15 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use. The main questions the study aims to answer are: Is TOMAC™ PNS a feasible and acceptable intervention for RLS in pregnant individuals? Are there any maternal, fetal, or neonatal safety concerns with PNS use during pregnancy? What are the patterns of adherence, tolerance, and usability of the TOMAC™ device in this population? Participants will: Use a non-invasive TOMAC™ peroneal nerve stimulator during 30-minute sessions as needed, for 8 weeks. Complete questionnaires assessing feasibility, acceptability, symptom severity, and sleep quality (including AIM, IAM, FIM, IRLS, PGI-I, PSQI, ESS, FOSQ, and MOS-II). Wear an actigraphy monitor to collect objective sleep data at baseline and at 4 weeks. Attend scheduled follow-up visits and phone check-ins for maternal vital signs, uterine contraction and fetal monitoring, and neonatal outcome assessment. This is a prospective, open-label, single-arm pilot study enrolling 15 pregnant participants between 21 and 26 weeks' gestation. Findings will provide the first dataset on the feasibility, acceptability, and safety of TOMAC™ PNS in pregnancy and inform the design of a future randomized controlled trial.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Pregnant individuals between 21 and 26 weeks' gestation at enrollment * Singleton pregnancy without known fetal anomalies * Confirmed clinical diagnosis of Restless Legs Syndrome (RLS) according to International Restless Legs Syndrome Study Group (IRLSSG) criteria, confirmed by a sleep medicine specialist to exclude RLS mimics * Able and willing to provide informed consent * Able and willing to comply with study procedures, including device usage, questionnaires, adherence diaries, and follow-up assessments up to 3 months postpartum Exclusion Criteria: Pregnancy-related: * History of preterm labor * Known fetal anomalies identified prior to enrollment Neurological and neuromuscular disorders: * Pre-existing neuromuscular disorders affecting balance or gait * Severe peripheral neuropathy involving the lower legs * Epilepsy or history of seizures Cardiovascular and circulatory conditions: * History of deep vein thrombosis (DVT) * Circulatory conditions contraindicating peroneal nerve stimulation (PNS) device use Dermatological conditions: * Skin conditions at device application sites * Known allergy to device materials Other sleep disorders: • Inadequately treated severe primary sleep disorders other than RLS (e.g., untreated severe sleep apnea, severe insomnia unrelated to RLS) Device and treatment experience exclusions (based on RESTFUL trial criteria): * Prior use of the study device or any neurostimulation device for RLS treatment * Presence of active medical implants (e.g., pacemakers, spinal cord stimulators) Other medical conditions: * Participants undergoing dialysis treatment * Severe psychiatric conditions (e.g., bipolar disorder, psychosis, severe anxiety or depression) that may interfere with adherence or accurate symptom reporting * Any condition deemed by investigators to pose safety risks or impede participation Other exclusions: * Unable or unwilling to operate the device safely and independently * Unable to participate reliably in follow-up assessments or complete self-reported diaries
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07144631 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Restless Leg Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07144631 currently recruiting?
Yes, NCT07144631 is actively recruiting participants. Contact the research team at vbuntak@brownhealth.org for enrollment information.
Where is the NCT07144631 trial being conducted?
This trial is being conducted at Providence, United States, Providence, United States.
Who is sponsoring the NCT07144631 clinical trial?
NCT07144631 is sponsored by Rhode Island Hospital. The trial plans to enroll 15 participants.